DUSAVI Trademark

Trademark Overview


On Wednesday, October 11, 2017, a trademark application was filed for DUSAVI with the United States Patent and Trademark Office. The USPTO has given the DUSAVI trademark a serial number of 87641236. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Monday, September 20, 2021. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The DUSAVI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ...
dusavi

General Information


Serial Number87641236
Word MarkDUSAVI
Filing DateWednesday, October 11, 2017
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateMonday, September 20, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, October 18, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNorth Wales, PA 19454

Trademark Events


Event DateEvent Description
Monday, September 20, 2021ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Monday, September 20, 2021ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Monday, March 8, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, March 8, 2021NON-FINAL ACTION E-MAILED
Monday, March 8, 2021NON-FINAL ACTION WRITTEN
Monday, March 8, 2021LIE CHECKED SUSP - TO ATTY FOR ACTION
Wednesday, July 15, 2020REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Tuesday, January 14, 2020REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Thursday, July 11, 2019REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Friday, January 11, 2019REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Friday, January 11, 2019ASSIGNED TO LIE
Thursday, June 7, 2018UNDELIVERABLE MAIL - COURTESY COPY MAILED
Thursday, May 31, 2018NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, May 31, 2018LETTER OF SUSPENSION E-MAILED
Thursday, May 31, 2018SUSPENSION LETTER WRITTEN
Wednesday, May 30, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, May 29, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, May 29, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, January 11, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, January 11, 2018NON-FINAL ACTION E-MAILED
Thursday, January 11, 2018NON-FINAL ACTION WRITTEN
Wednesday, January 10, 2018ASSIGNED TO EXAMINER
Wednesday, October 18, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, October 14, 2017NEW APPLICATION ENTERED IN TRAM